News archive
Showing 692 results
April 2013
-
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
- Discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the Government- Physician speaker programs are also an accepted practice designed… -
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
March 2013
-
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine- TOBI Podhaler is indicated for certain cystic fibrosis (CF) patients with Pa and shortens… -
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral… -
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
February 2013
-
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU)- CIU can be a serious, debilitating form of hives… -
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
- Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation- Approval based on… -
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients